Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Arzneimittel-Forschung|January 1, 1985
Pharmacology of mifentidine, a novel H2-receptor antagonistF Pagani, R Micheletti, A Brambilla, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1988
Binding and functional characterization of the cardioselective muscarinic antagonist methoctramineE Giraldo, R Micheletti, E Montagna, et al.
European Journal of Pharmacology|October 15, 1991
Pharmacological properties of a novel class of 5-HT3 receptor antagonistsM Turconi, A Donetti, A Schiavone, et al.
ESMO Open|December 5, 2021
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trialsE Munzone, E Pagan, V Bagnardi, et al.
The Journal of Biological Chemistry|July 14, 1995
The nitric oxide transduction pathway in Trypanosoma cruziC Paveto, C Pereira, J Espinosa, et al.
The Journal of Eukaryotic Microbiology|May 1, 1995
Adenylyl cyclase and G-proteins in PhytomonasM D Farber, A E Montagna, C Paveto, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2008
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumabE Montagna, G Cancello, D D'Agostino, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiationA Sagrada, M Turconi, P Bonali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2009
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancerM Colleoni, V Bagnardi, N Rotmensz, et al.
British Journal of Cancer|May 29, 2008
Factors that predict early treatment failure for patients with locally advanced (T4) breast cancerE Montagna, V Bagnardi, N Rotmensz, et al.
Pageof 4